XML 36 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Reporting
3 Months Ended
Sep. 30, 2021
Segment Reporting  
Segment Reporting

17. Segment reporting

The Company’s chief operating decision maker (“CODM”), who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews

financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance.

The Company manages and aggregates its operational and financial information in accordance with two reportable segments: Aytu BioPharma and Aytu Consumer Health. The Aytu BioPharma segment consists of the Company’s prescription products. The Aytu Consumer Health segment contains the Company’s consumer healthcare products.

Select financial information for these segments is as follows:

Three Months Ended

September 30, 

2021

    

2020

(In thousands)

Consolidated revenue:

  

 

  

Aytu BioPharma

$

13,883

$

5,752

Aytu Consumer Health

 

8,014

 

7,768

Consolidated revenue

$

21,897

$

13,520

Consolidated net loss:

 

  

 

  

Aytu BioPharma

$

(26,457)

$

(2,950)

Aytu Consumer Health

 

(1,394)

 

(1,356)

Consolidated net loss

$

(27,851)

$

(4,306)

September 30, 

June 30, 

2021

2021

(In thousands)

Total assets:

 

  

 

  

Aytu BioPharma

$

198,685

$

236,449

Aytu Consumer Health

 

29,044

 

29,219

Consolidated assets

$

227,729

$

265,668